CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade PT Kalbe Farma Tbk. - PTKFF CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Kalbe Farma Tbk PT ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 1,520.00-2,150.00
Average Volume (10 days) 29.19M
Average Volume (3 months) 969.21M
Market Cap 96,094.00B
P/E Ratio 28.26
Shares Outstanding 46.26B
Revenue 28,344.30B
EPS 72.55
Dividend (Yield %) 1.70732
Beta 0.61
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low

PT Kalbe Farma Tbk. Events

Time (UTC) Country Event
Tuesday, October 31, 2023

Time (UTC)

10:59

Country

ID

Event

Q3 2023 Kalbe Farma Tbk PT Earnings Release
Q3 2023 Kalbe Farma Tbk PT Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 28933500 26261200 23112700 22633500 21074300
Revenue 28933500 26261200 23112700 22633500 21074300
Cost of Revenue, Total 17498700 15157800 13062900 12607300 11337500
Gross Profit 11434800 11103400 10049700 10026200 9736770
Total Operating Expense 24537900 22250600 19560700 19333500 17861300
Selling/General/Admin. Expenses, Total 6237130 6080150 5530130 5740040 5516470
Research & Development 431804 487769 441755 511409 477039
Depreciation / Amortization 381501 380060 372916 298253 283444
Interest Expense (Income) - Net Operating -167938 -283.254 -72269.9 10497.2 -29359
Unusual Expense (Income) -5181.88 -15057.1 74238.9 -5974 -10367.7
Other Operating Expenses, Total 161814 160126 151022 171970 286514
Operating Income 4395630 4010630 3551930 3299960 3213030
Interest Income (Expense), Net Non-Operating 77099.7 145376 97420.9 112018 103454
Other, Net -13833.4 -12736.5 -21715.8 -9365.12 -10079.5
Net Income Before Taxes 4458900 4143260 3627630 3402620 3306400
Net Income After Taxes 3450080 3232010 2799620 2537600 2497260
Minority Interest -67873.6 -48386.4 -66362.6 -30837.3 -40132.9
Net Income Before Extra. Items 3382210 3183620 2733260 2506760 2457130
Net Income 3382210 3183620 2733260 2506760 2457130
Income Available to Common Excl. Extra. Items 3382210 3183620 2733260 2506760 2457130
Income Available to Common Incl. Extra. Items 3382210 3183620 2733260 2506760 2457130
Diluted Net Income 3382210 3183620 2733260 2506760 2457130
Diluted Weighted Average Shares 46515.9 46872.9 46873.4 46875.1 46875.1
Diluted EPS Excluding Extraordinary Items 72.7108 67.9202 58.3115 53.4775 52.4186
Dividends per Share - Common Stock Primary Issue 38 35 34 20 26
Diluted Normalized EPS 72.6246 67.6696 59.5338 53.3825 54.0426
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 7309770 7869160 7751730 7307180 6858880
Revenue 7309770 7869160 7751730 7307180 6858880
Cost of Revenue, Total 4440040 4722110 4919180 4411720 4046850
Gross Profit 2869730 3147050 2832550 2895470 2812030
Total Operating Expense 6469850 6783400 6539380 6205750 5842960
Selling/General/Admin. Expenses, Total 1691620 1761840 1492820 1543400 1607910
Research & Development 191685 134373 72426.9 130720 112016
Depreciation / Amortization 96264 94558.4 92320.1 98515.7 97905
Interest Expense (Income) - Net Operating 26104.9 34495.5 -84359.3 -33067.7 -39025.3
Unusual Expense (Income) -88.0182 -1091.01 -2243.9 -684.344
Other Operating Expenses, Total 24136.1 36111 48081.4 56708.7 17989
Operating Income 839918 1085760 1212350 1101440 1015920
Interest Income (Expense), Net Non-Operating 5241.15 14610.8 15592.1 2378.35 30054
Other, Net -1710.26 -4406.31 -5491.62 -3051.17 -2546.06
Net Income Before Taxes 843449 1095960 1222450 1100760 1043430
Net Income After Taxes 662794 853873 915868 861463 820088
Minority Interest 10486 1843.8 -19172.3 -12897.8 -18021.3
Net Income Before Extra. Items 673280 855717 896696 848565 802067
Net Income 673280 855717 896696 848565 802067
Income Available to Common Excl. Extra. Items 673280 855717 896696 848565 802067
Income Available to Common Incl. Extra. Items 673280 855717 896696 848565 802067
Diluted Net Income 673280 855717 896696 848565 802067
Diluted Weighted Average Shares 46515.9 46515.9 46515.9 46299.2 46464.7
Diluted EPS Excluding Extraordinary Items 14.4742 18.3962 19.2772 18.3279 17.2619
Dividends per Share - Common Stock Primary Issue 0 0 38 0 0
Diluted Normalized EPS 14.4742 18.3947 19.2596 18.2899 17.2503
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 16710200 15712200 13075300 11222500 10648300
Cash and Short Term Investments 4095080 6475170 5396250 3236110 3332050
Cash 1634560 2892560 2324850 980905 785338
Cash & Equivalents 2315210 3323690 2883080 2059580 2367990
Short Term Investments 145307 258923 188316 195619 178719
Total Receivables, Net 4787770 3545140 3594930 3697660 3373570
Accounts Receivable - Trade, Net 4613620 3431020 3477220 3572850 3255540
Total Inventory 7027360 5087300 3599750 3737980 3474590
Prepaid Expenses 731689 558900 435851 495586 419053
Other Current Assets, Total 68338.6 45695.8 48562.3 55162.9 49032.3
Total Assets 27241300 25666600 22564300 20264700 18146200
Property/Plant/Equipment, Total - Net 8333170 8322760 8310140 7666310 6252800
Property/Plant/Equipment, Total - Gross 13542600 12781100 12305200 11185700 9407830
Accumulated Depreciation, Total -5209440 -4458300 -3995050 -3519370 -3155030
Goodwill, Net 479347 209684 195226 293280 293280
Intangibles, Net 1026050 923048 464792 369273 140161
Long Term Investments 384543 303272 123338 91063.7 86106.4
Note Receivable - Long Term 93178.2 43576.1 35246.7 52685.5 54345.4
Other Long Term Assets, Total 214802 152086 360221 569619 671224
Total Current Liabilities 4431040 3534660 3176730 2577110 2286170
Accounts Payable 1996610 1667600 1240390 1215860 1289900
Accrued Expenses 601327 710937 481949 469464 301100
Notes Payable/Short Term Debt 705600 0 220500 149638 69154.7
Current Port. of LT Debt/Capital Leases 150219 93645.6 148764 19518.8 28251.2
Other Current Liabilities, Total 977278 1062480 1085130 722627 597764
Total Liabilities 6856100 6087110 5158770 4371600 3522750
Total Long Term Debt 311899 532510 788552 647688 260002
Long Term Debt 287031 490277 722819 647648 259831
Capital Lease Obligations 24868 42232.4 65732.4 40.8689 170.594
Deferred Income Tax 32500.2 19572.5 2590.63 241.581 129.249
Minority Interest 1712110 1686350 870549 812456 671137
Other Liabilities, Total 368547 314019 320350 334106 305313
Total Equity 20385200 19579500 17405500 15893100 14623500
Common Stock 468751 468751 468751 468751 468751
Additional Paid-In Capital -34118.7 -34118.7 -34118.7 -34118.7 -34118.7
Retained Earnings (Accumulated Deficit) 20497700 18746800 16875700 15361100 14073100
Unrealized Gain (Loss) 101896 73994.1 39111.3 56006.2 42056.4
Other Equity, Total 354924 326113 58181.5 41367.2 73659.9
Total Liabilities & Shareholders’ Equity 27241300 25666600 22564300 20264700 18146200
Total Common Shares Outstanding 46255.6 46872.9 46872.9 46875.1 46875.1
Treasury Stock - Common -1003970 -2063.2 -2063.2
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 17568000 16710200 16149400 15296900 16878100
Cash and Short Term Investments 3626610 4095080 4312080 4347760 6627180
Cash 1499350 1634560 2556490 2071030 2987500
Cash & Equivalents 1981600 2315210 1587420 2062460 3379570
Short Term Investments 145655 145307 168177 214274 260104
Total Receivables, Net 5390280 4787770 4459570 4171540 3953110
Accounts Receivable - Trade, Net 5247150 4613620 4319320 4025510 3820560
Total Inventory 7636260 7027360 6641200 6024020 5627150
Prepaid Expenses 862706 731689 675314 699379 612472
Other Current Assets, Total 52163.1 68338.6 61265 54162.3 58191.8
Total Assets 28239700 27241300 26187200 25263300 26861600
Property/Plant/Equipment, Total - Net 8334210 8333170 8270090 8220250 8332260
Property/Plant/Equipment, Total - Gross 13698700 13542600 13163200 12961400 12896100
Accumulated Depreciation, Total -5364480 -5209440 -4893160 -4741160 -4563860
Goodwill, Net 479347 479347 209684 209684 209684
Intangibles, Net 1032790 1026050 974465 956660 932918
Long Term Investments 511473 384543 367689 370980 315481
Note Receivable - Long Term 89220.7 93178.2 48413.5 51743.6 38212.4
Other Long Term Assets, Total 224618 214802 167382 157164 154935
Total Current Liabilities 4611540 4431040 4253260 3747340 4040390
Accounts Payable 2460570 1996610 1967160 1903690 1943820
Accrued Expenses 596959 601327 835694 805850 782814
Notes Payable/Short Term Debt 465400 705600 595000 110000 152000
Current Port. of LT Debt/Capital Leases 123860 150219 59194.1 72069.4 80334.4
Other Current Liabilities, Total 964748 977278 796212 855736 1081420
Total Liabilities 7039340 6856100 6716380 6213060 6619830
Total Long Term Debt 299310 311899 430753 439904 526909
Long Term Debt 280212 287031 400400 407668 486319
Capital Lease Obligations 19098.2 24868 30353 32235.9 40590.1
Deferred Income Tax 36340.7 32500.2 34226.9 28463.6 29580.9
Minority Interest 1720850 1712110 1678040 1679530 1704230
Other Liabilities, Total 371298 368547 320094 317822 318723
Total Equity 21200300 20385200 19470800 19050300 20241800
Common Stock 468751 468751 468751 468751 468751
Additional Paid-In Capital -34118.7 -34118.7 -34118.7 -34118.7 -34118.7
Retained Earnings (Accumulated Deficit) 21353500 20497700 19601000 18752500 19581700
Treasury Stock - Common -1003970 -1003970 -1003970 -588396 -179960
Unrealized Gain (Loss) 100713 101896 106015 106446 73912.6
Other Equity, Total 315516 354924 333061 345125 331433
Total Liabilities & Shareholders’ Equity 28239700 27241300 26187200 25263300 26861600
Total Common Shares Outstanding 46255.6 46255.6 46255.6 46508.8 46762.9
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Cash From Operating Activities 1271890 2825950 4214740 2502970 2770780
Cash Receipts 31327400 28936600 25453500 24423100 22705200
Cash Payments -19106900 -15917400 -12407600 -12316400 -10798800
Cash Taxes Paid -1152780 -965742 -592189 -818595 -835148
Changes in Working Capital -9795850 -9227540 -8239060 -8785210 -8300460
Cash From Investing Activities -1370390 -1056020 -951215 -1900540 -1289830
Capital Expenditures -870100 -1000870 -1118200 -1982930 -1373030
Other Investing Cash Flow Items, Total -500290 -55149.2 166989 82385.1 83202.9
Cash From Financing Activities -2405750 -745176 -1099710 -706915 -1139660
Financing Cash Flow Items -36101.4 1160700 -80466.4 95863 -9615.64
Total Cash Dividends Paid -1687680 -1372680 -1252230 -1218750 -1171880
Issuance (Retirement) of Debt, Net 319937 -533194 235052 415975 41836
Foreign Exchange Effects 237776 -16432.5 51263.6 -51836.1 26952
Net Change in Cash -2266480 1008320 2215080 -156324 368242
Issuance (Retirement) of Stock, Net -1001910 0 -2063.2
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Cash From Operating Activities 199521 1271890 577781 333318 336195
Cash Receipts 8114210 31327400 22539500 14717900 7336630
Cash Payments -4981690 -19106900 -13996500 -8949310 -4364840
Cash Taxes Paid -143623 -1152780 -777153 -573965 -162393
Changes in Working Capital -2789380 -9795850 -7188090 -4861330 -2473210
Cash From Investing Activities -297969 -1370390 -466102 -258284 -135934
Capital Expenditures -192626 -870100 -619489 -350963 -157932
Other Investing Cash Flow Items, Total -105343 -500290 153387 92679.7 21998.4
Cash From Financing Activities -292885 -2405750 -2284310 -2218480 -61361.2
Financing Cash Flow Items -13090.2 -36101.4 -34727.4 -23388.5 -11647.8
Issuance (Retirement) of Stock, Net 0 -1001910 -1001910 -586333 -177897
Issuance (Retirement) of Debt, Net -279795 319937 440009 -15426.7 128184
Foreign Exchange Effects -77482.9 237776 100285 60684.6 11923.4
Net Change in Cash -468815 -2266480 -2072340 -2082760 150824
Total Cash Dividends Paid -1687680 -1687680 -1593330

PT Kalbe Farma Tbk. Company profile

About Kalbe Farma Tbk PT

PT Kalbe Farma Tbk is an Indonesia-based pharmaceutical company. The Company provides healthcare solution through its four business divisions: the prescription pharmaceutical division, consumer health, nutritional, and distribution and logistics divisions. Its Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over-the-counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments: infants, toddlers, children, pre-teenagers, teenagers, adults, pregnant and lactating women. Its Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

Financial summary

BRIEF: For the nine months ended 30 September 2021, KalbeFarma Tbk PT revenues increased 12% to RP19.099T. Netincome increased 13% to RP2.288T. Revenues reflectDistribution and Logistics segment increase of 24% toRP6.816T, Prescription Pharmaceutical segment increase of11% to RP4.191T, Domestic segment increase of 12% toRP18.214T, Export segment increase of 3% to RP884.72B.

Equity composition

01/2004, 2-for-1 stock split. 11/00 1.88-for-1 stock split.FY 04 Financials are restated. FY 05 Qs & 06 financials arerestated. FY 06 Qs are restated. 1 Nov 07, Co refiledQ3 07. No changes in financials. 24 March 09, Co refiledQ3 07. No changes in financials. 10/2012, Split 1-for-5 newshares (fac:5).

Industry: Pharmaceuticals (NEC)

Gedung KALBE Let.Jend Suprato Kav. 4
JAKARTA
DKI JAKARTA
ID

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

Oil - Crude

90.14 Price
+0.770% 1D Chg, %
Long position overnight fee 0.0415%
Short position overnight fee -0.0634%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
+0.700% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

US100

14,710.90 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

1,598.67 Price
+0.440% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading